摘要
目的 探讨阿帕替尼治疗晚期恶性肿瘤的临床效果及对患者血压的影响.方法 选取2016年1月1日~2017年12月31日我院收治的42例晚期恶性肿瘤患者作为研究对象,按照随机抽签方法分为两组,每组各21例,对照组给予安慰剂及营养支持治疗,观察组在对照组基础上给予阿帕替尼治疗.对两组患者的总有效率及不良反应发生情况、高血压分级进行观察和评估.结果 观察组总有效率高于对照组,差异有统计学意义(P<0.05).观察组的不良反应总发生率高于对照组,差异有统计学意义(P<0.05).观察组患者的高血压总发生率高于对照组,差异有统计学意义(P<0.05);两组患者的高血压分级情况比较,差异无统计学意义(P>0.05).结论 阿帕替尼应用于晚期恶性肿瘤患者中具有较高的临床应用价值,有利于延长生存期,但是高血压的临床发生率较高,其血压升高的机制有待于进一步探讨.
Objective To investigate the clinical effect of Apatinib in the treatment of advanced malignant tumors and its effect on blood pressure.Methods Forty-two patients with advanced malignant tumors admitted to our hospital from January 1,2016 to December 31,2017 were enrolled in the study.They were divided into two groups according to random sampling,21 cases each group.The control group received placebo and nutritional support treatment.The observation group was treated with Apatinib on the basis of the control group,and the total effective rate,adverse reactions,and grade of hypertension were observed and evaluated.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).The total incidence of adverse reactions in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).The total incidence of hypertension in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the grade of hypertension between the two groups(P>0.05).Conclusion Apatinib has high clinical value in patients with advanced malignant tumors,which is beneficial to prolonging survival.However,the clinical incidence of hypertension is high,and the mechanism of blood pressure elevation needs further discussion.
作者
周均
徐海龄
华敏
周元风
平祥华
ZHOU Jun;XU Hai-ling;HUA Min;ZHOU Yuan-feng;PING Xiang-hua(Department of Cardiovascular Medicine,the Third People′s Hospital of Jiujiang City,Jiangxi Province,Jiujiang 332000,China)
出处
《中国当代医药》
2020年第8期66-68,共3页
China Modern Medicine
基金
江西省卫生计生委科技计划项目(20197146)。
